Evidence map›Paper›PMID 42850709›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Tumor-Intrinsic HEXB Drives Endothelial-To-Mesenchymal Transition and Confers Resistance to Anti-Angiogenic Therapy in Glioblastoma.

Tianqi Liu, Xin Chen, Tao Sun, Jianqi Wu, Haixu Yan, Xing Liu, Hongda Lin, Xiangyu Wang, Ziao Xiao, Yang Xu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tianqi Liu *Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Xin Chen *Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Tao Sun *Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Jianqi Wu *Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Haixu YanDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Xing LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Hongda LinDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Xiangyu WangDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Ziao XiaoDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Yang XuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Qiang FuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Peng ChengDepartment of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Wen ChengDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.ORCID https://orcid.org/0000-0003-0689-1695
Anhua WuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.ORCID https://orcid.org/0000-0002-3402-1884

Funding

Joint Project of Liaoning Province 2023JH2/101700168Joint Project of Liaoning Province 2023JH2/101700202National Natural Science Foundation of China 82303346National Natural Science Foundation of China 82303837National Natural Science Foundation of China 82373342National Natural Science Foundation of China 82403452National Natural Science Foundation of China 82472833National Natural Science Foundation of China 82573052Science and Technology Planning Project of Liaoning Province 2021JH1/10400049Shengjing Hospital of China Medical University 345 Talent Project 1000801592
6 · The paper itself

Abstract

Although anti-angiogenic (anti-VEGF) therapy is widely used for glioblastoma (GBM), its efficacy is severely limited by acquired resistance. Here, we identify endothelial-mesenchymal transition (Endo-MT) in brain endothelial cells as the primary driver of this resistance, fundamentally modulated by hexosaminidase B (HEXB). Mechanistically, HEXB directly binds and stabilizes heat shock protein 60 (HSP60) by inhibiting its ubiquitination and degradation. This stabilization upregulates insulin-like growth factor binding protein 1 (IGFBP1), thereby promoting the Endo-MT process. Addressing its clinical relevance, the combination of a HEXB inhibitor and anti-VEGF therapy exerts potent synergistic therapeutic effects in GBM murine models. Overall, our study establishes HEXB as a key driver of Endo-MT and provides a promising dual-targeting strategy to overcome anti-VEGF resistance in GBM.

Indexed as

anti‐VEGF therapyendothelial‐mesenchymal transitionglioblastomaHEXBHSP60ubiquitination

Identifiers

PMID42850709

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.